RESEARCH TRIANGLE PARK, NC, May 19 /CNW/ - Patheon Inc. (TSX: PTI), a
global provider of drug development and manufacturing services to the
international pharmaceutical industry, is pleased to announce the introduction
of cell based assay services to support biopharmaceutical product development.
The new services will strengthen Patheon's existing analytical capability
in biopharmaceutical analysis. Cell based assays are a key technology used in
determining the biological potency of biopharmaceuticals required for product
licensing procedures. Biological potency analytics and the required supporting
capabilities for tissue culture, such as assessment of cell viability and
production of master and working cell banks, will take place at Patheon's
Swindon, UK facility. This will enable all the analytical needs for
biopharmaceutical product development to be completed in one location.
Wes Wheeler, President and CEO of Patheon Inc. stated, "Expanding the
services provided through using cell based assays at our Swindon facility, is
a testament to the commitment Patheon has to enhancing and growing the
Pharmaceutical Development Services provided to our customers. This new
capability allows us to better meet the needs of customers in the early stages
of drug development."
The facility will be managed and supported by a team of scientists with
approximately 18 years of combined experience in tissue culture and cell based
assays. The facility will be fully available for use at the end of May.
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API. Patheon's integrated network strives to
ensure that customer products can be launched with confidence globally.
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
For further information:
For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (919) 226-3200, Email: email@example.com; Mr. Eric Evans,
Chief Financial Officer, Tel: (919) 226-3200, Email: firstname.lastname@example.org;
Mr. Norman Barras, Vice President, PDS Europe, Tel: +44(0)7725 423431, Email: